Feb 14, 2023
Interim Phase 1 results from enGene's Phase 1/2 LEGEND study of intravesical EG-70 (detalimogene voraplasmid) demonstrate a 71% CR rate at three months in patients with high-grade non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) that is BCG-unresponsive.
Feb 02, 2023
enGene, Inc. today announced that Alex Nichols, PhD, has joined the company as President and Chief Operating Officer.
Mar 17, 2022
enGene Inc. today announced the appointment of James C. Sullivan, PhD, as its Chief Scientific Officer (CSO). In his role as CSO, Dr. Sullivan will lead research and development efforts that focus on new ways to expand the use of the company's gene therapy platform and assets.
enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by it proprietary DDX platform, today announced positive results from its LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 for the treatment of high-grade Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with carcinoma in situ (CIS) that are BCG-unresponsive.
enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced a poster presentation at the upcoming Society of Urologic Oncology Annual Meeting being held from December 1 to December 3, 2021.
enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enable by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first in human Phase 1/2 clinical trial of EG-70 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).